Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2016-11-10 Interim / Quarterly Rep…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the first nine months (9M) of 2016 for Evotec AG. It contains detailed financial statements, including a condensed income statement, segment information, and balance sheet data. It is not an announcement of a report, but the report itself, containing substantive financial analysis and actual financial data. Therefore, it fits the definition of an Interim/Quarterly Report. 9M 2016
2016-11-10 German
EVOTEC TO REPORT FIRST NINE-MONTH 2016 RESULTS ON 10 NOVEMBER 2016
Report Publication Announcement Classification · 99% confidence The document is a short press release dated November 3, 2016, announcing that Evotec AG will report its financial results for the first nine months of 2016 on November 10, 2016, and will hold a conference call to discuss them. This is not the actual financial report (which would be an IR or ER), but rather an announcement about the *timing* of the release of results and the associated conference call details. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement detailing the publication of a report falls under Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because it fits the specific RPA category.
2016-11-03 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections like 'Notification of Major Holdings', detailing changes in voting rights percentages (3.23%) held by a shareholder (Ministry of Finance on behalf of the State of Norway/Norges Bank). This directly corresponds to the definition of a major shareholding notification or a voting rights announcement. Given the specific category 'Declaration of Voting Results & Voting Rights Announcements' (DVA) and 'Major Shareholding Notification' (MRQ), I must choose the most precise fit. Since the core content is the notification of crossing a voting rights threshold (Sec. 26, Section 1 of WpHG), MRQ (Major Shareholding Notification) is highly relevant, but DVA specifically covers 'Voting Rights Announcements'. In many regulatory contexts, these are grouped. However, the structure strongly aligns with reporting changes in ownership thresholds, which is the primary function of an MRQ. Looking at the definitions, MRQ is 'Notification of changes in significant share ownership levels (crossing thresholds)'. DVA is 'Official results from shareholder votes at any general meeting (AGM or EGM)'. Since this is a notification of a holding change, not the result of a vote, MRQ is the better fit, although the header mentions 'Voting Rights Announcements'. Given the detailed structure matching ownership reporting rules (WpHG Sec. 21, 22, 25), MRQ is the most accurate classification for this type of filing.
2016-10-31 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It announces the 'New total number of voting rights' (132,964,272) following a 'Conditional capital increase' or 'Other capital measure'. This type of announcement, which reports on changes related to voting rights or capital structure, fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS). Since it specifically details a change in the total number of voting rights due to a capital measure, 'CAP' (Capital/Financing Update) is the most precise fit, as it relates directly to the capital structure. However, looking closely at the provided definitions, there isn't a specific code for 'Total Voting Rights Announcement'. - CAP (Capital/Financing Update): Covers fundraising, financing, or capital structure changes. A change in total voting rights due to a capital increase fits here. - DVA (Declaration of Voting Results & Voting Rights Announcements): This is for *results* from shareholder votes, not the announcement of the total number of rights. - SHA (Share Issue/Capital Change): This covers new share issues or stock splits. A conditional capital increase leading to a change in total rights is closely related. Given the focus on the *total number of voting rights* resulting from a capital measure, CAP is a strong candidate. However, if we consider the nature of the announcement as a mandatory regulatory disclosure about the share base, it often falls under general regulatory announcements if a more specific code isn't available. Since the document explicitly details a change in the capital structure (conditional capital increase leading to a new total count), CAP is the most relevant category among the choices provided for capital structure changes. Revisiting the definitions, 'CAP' is for fundraising/financing/capital structure changes. 'SHA' is for share issue/capital change. The document reports the *result* of a capital measure on the total voting rights. Both CAP and SHA are plausible. Given the context of a mandatory disclosure about the total share count, and the explicit mention of a 'capital measure', I will lean towards CAP as it broadly covers capital structure updates, which this directly impacts.
2016-10-31 English
EVOTEC ANNOUNCES ITS INTENT TO ACQUIRE CYPROTEX PLC
M&A Activity Classification · 99% confidence The document is a press release dated October 26, 2016, announcing Evotec AG's intent to acquire Cyprotex PLC. The content details the terms of the acquisition (cash offer, premium, expected closing date) and the strategic rationale. This clearly falls under the category of a significant corporate action related to mergers and acquisitions (M&A). The filing type code corresponding to M&A Activity is TAR.
2016-10-26 English
Evotec AG announces its intent to acquire Cyprotex PLC
M&A Activity Classification · 98% confidence The document explicitly states 'Evotec AG announces its intent to acquire Cyprotex PLC' and discusses the offer price, premium, and regulatory framework ('UK takeover code'). This content directly relates to a merger or takeover proposal. Based on the definitions, the appropriate code is TAR (M&A Activity). The document is a formal announcement detailing the transaction terms, not just a notice that a report is available.
2016-10-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.